Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00743002 | A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione | PHASE2 | COMPLETED | 87 | — | — | Aug 1, 2008 | Dec 1, 2009 | Jun 21, 2013 | 20 | United States |
| Arm | Type | Description |
|---|---|---|
| TT223 with Metformin and/or TZD | EXPERIMENTAL | TT223 as a treatment for Type 2 diabetes is administered by injection once daily at 1 mg, 2 mg and 3 mg patients currently treated with Metformin and/or Thiazolidinedione (TZD). |
| Placebo with Metformin and/or TZD | PLACEBO_COMPARATOR | Placebo as a comparator is administered by injection once daily at 1 mg, 2 mg and 3 mg patients currently treated with Metformin and/or Thiazolidinedione (TZD). |
| Name | Type | Description |
|---|---|---|
| TT223 with Metformin and/or TZD | DRUG | Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks |
| Placebo with Metformin and/or TZD | DRUG | Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks |
Inclusion Criteria: * Type 2 Diabetes for at least 6 months * Treated with metformin and/or thiazolidinediones with stable dose for at least 3 months * BMI of 21-45 kg/m2, inclusive * HbA1c level of 7.50 - 10.00%, inclusive * If a female of childbearing potential, willing to utilize contraception f...